NCT06879717View on ClinicalTrials.gov

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Advanced Non Squamous NSCLC
Interventions
DRUG

roginolisib

tablet, 40mg tablet strength

DRUG

Dostarlimab

500 mg administered as IV infusion

DRUG

Docetaxel

75 mg/m2 administered over 1 hour as IV infusion

Trial Locations (7)

2650

NOT_YET_RECRUITING

Antwerp University Hospital, Antwerp

8800

NOT_YET_RECRUITING

AZ Delta VZW, Roeselare

20072

NOT_YET_RECRUITING

Humanitas University, Department of Medical Oncology, Rozzano

46026

NOT_YET_RECRUITING

Hospital Universitario y Politécnico La Fe, Valencia

47014

NOT_YET_RECRUITING

"Istituto Romagnolo per lo studio dei Tumori Dino Amadori", Meldola

08908

NOT_YET_RECRUITING

Institut Català d'Oncologia Hospitalet, Barcelona

07120

RECRUITING

Hospital Universitari Son Espases, Palma

Sponsors

Lead Sponsor

iOnctura
All Listed Sponsors
lead

iOnctura

INDUSTRY

NCT06879717 - A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | Biotech Hunter | Biotech Hunter